Pune-based Gennova Biopharmaceuticals plans to kick off early- to mid-stage human trials of its Covid-19 vaccine candidate “soon”, enrolling around 620 participants across several sites over the next few months.
“We have started the processes. We hope to start phase 1 soon. We will present our phase 1 data to the DCGI (Drug Controller General of India), before starting the second phase, and so the timeline for the trials to be completed will depend on these factors,” said Gennova CEO Dr Sanjay Singh.(Follow Covid-19 Live Updates here)